EVALUATION OF CHEMOPREVENTIVE AGENTS BY IN VITRO TECHNIQUES

NIH GUIDE, Volume 23, Number 3, January 21, 1994



MAA AVAILABLE:  NCI-CN-45581-70



P.T. 34



Keywords:

  Cancer/Carcinogenesis 

  Chemopreventive Agents 

  Bioassay 



National Cancer Institute



The Chemoprevention Branch, Division of Cancer Prevention and Control

(DCPC), National Cancer Institute (NCI), in its annual requirement to

seek new sources, is soliciting proposals for the Evaluation of

Chemopreventive Agents by In Vitro Techniques to increase the number

of Master Agreement (MA) Holders.  Current MA Holders for this

program are not required to submit a proposal.  This Master Agreement

Announcement (MAA) is issued to solicit MA Holders who have adequate

capabilities and technical expertise to screen and evaluate the

activity of chemopreventive agents in various in vitro assays of cell

transformation.  Agents with potential chemopreventive activity are

identified by epidemiologic surveys, initial laboratory

(experimental) findings, observations in the clinical setting, or

structural homology with agents having known chemopreventive

activity.  A rigorous and systematic evaluation of these candidate

agents is necessary before their efficacy can be examined in clinical

trials for cancer prevention.  In vitro screening and evaluation

techniques measuring the ability of these chemopreventive agents to

inhibit transformation provides a relatively rapid and efficient

means of qualifying these agents for further evaluation for the

prevention of cancer in humans.  Agents to be investigated by this

project are potentially hazardous.  The in vitro systems may involve

the use of carcinogens, tumor cells, or tumor viruses.  Laboratory

practices will be employed, which will keep any element of risk to

personnel at an absolute minimum.  Where indicated, tissue and

compound handling must be performed in (at least) Class I laminar

flow cabinets that must meet NIH specifications for work with these

agents.  The offeror will comply with NCI safety standards for

research involving chemical carcinogens (DHHS Publication No. NIH

76-900 and the FDA Good Laboratory Practices Regulations).  It will

be required that the facilities have operating tissue culture/cell

biology and chemistry laboratories that are suitable for using

hazardous and/or carcinogenic materials as test materials.  The

contractor must have or be able to obtain all equipment necessary to

accomplish the studies including but not limited to, laminar flow

hoods, C02 incubators, equipment for sterility testing, isotope

counters, spectrophotometer, hazardous chemical storage cabinets and

refrigerators, equipment such as microscopes and miscellaneous

laboratory equipment.  The laboratory will have or have access to

appropriate terminal and computer facilities and equipment for data

collection and storage.  The period of performance of the MA pool

will be three years.  It is estimated that up to four Master

Agreement Orders per year will be issued pursuant to the Master

Agreements.



INQUIRIES



Requests for this solicitation must be in writing and reference MAA

No. NCI-CN-45581-70.  The MAA will be available approximately January

24, 1994 and due approximately February 24, 1994.  Requests are to be

addressed to:



Ms. Erin C. Lange

Research Contracts Branch, PCCS

National Cancer Institute

Executive Plaza South, Room 635

Bethesda, MD  20892

Telephone:  (301) 496-8603



.

Return to 1994 Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.